Cancer — Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Citation(s)
Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies